Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Study in 3 Parts to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients With Liver Cancer Manifestations

Next Previous
Trial Profile

A Phase 1/2a Study in 3 Parts to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients With Liver Cancer Manifestations

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fostroxacitabine bralpamide (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary)
  • Indications Cholangiocarcinoma; Liver cancer; Liver metastases
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Medivir AB

    • Most Recent Events

    • 29 Apr 2024 According to a Medivir AB media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) Gastrointestinal (GI) Cancers Congress by Dr Hong Jae Chon, CHA Bundang Medical Center in Korea. Dr Chon is one of the investigators in the ongoing phase Ib/IIa study.
    • 09 Apr 2024 According to a Medivir AB media release, CEO Jens Lindberg will present data from this study at the Investing in Oncology Forum on April 10, 2024.
    • 06 Mar 2024 According to a Medivir AB media release, CEO Jens Lindberg will present Medivir with focus on data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) and how these data enable an acceleration of fostrox's development program at the Swiss Nordic Bio conference on March 7, 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top